



Thursday – December 1st, 2011

14:00 – 15:30

Session: Retinal Vein Occlusion + Free Papers

Chair: B. Kuppermann, USA

Effect of Duration of ME Due to RVO on Outcomes after Treatment with Ozurdex in the RVO Studies

M. Goldstein, Israel

SCORE

M. Ip, USA

Lucentis/ Ranibizumab for Branch Retinal Vein Occlusion: BRAVO--Impact of Baseline Characteristics on Outcomes

A. Loewenstein, Israel

Lucentis/ Ranibizumab for Central Retinal Vein Occlusion: CRUISE--Impact of Baseline Characteristics on Outcomes

A. Loewenstein, Israel

VEGF-Trap Eye Trials for RVO--COPERNICUS and GALILEO

J. Heier, USA

HORIZON for RVO

J. Heier, USA

Ozurdex in Retinal Vein Occlusion: Duration of Effect and PRN Regimen

P. Lanzetta, Italy

14:00 – 14:45

Session: Conventional and Potential Glaucoma Therapy I + Free Papers

Chair: J. Jonas, Germany & H. Reitsamer, Austria

Autoimmune Phenomena in Glaucoma and Possible Implications for New Treatment Options

F. Grus, Germany

Neuroprotection and Axonal Neuroregeneration

R. Ellis-Behnke, USA

Sustained Drug Delivery Technologies for Glaucoma

T. Wong, Singapore

14:45 – 15:30

Session: Wound Healing / External Disease

Chair: P. Asbell, USA

FDA Lasik Study

M. Eydelman, USA (pending final FDA approval)

FDA TASS Proactive Program

M. Eydelman, USA (pending final FDA approval)

Keratoconus and Thyroid Hormones

B. Seitz, Germany





An Evaluation of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

G. Novack, USA

Equivalent Drugs, Different Outcomes: Clinical Experience and Precautions Using Generic Ophthalmics

J. Gayton, USA

UV Cross Linking: Evidence Based Review

P. Asbell, USA

15:30 – 16:00 **Coffee Break**

16:00 – 17:30 **Session: Dry AMD + Free Papers**
Chair: B. Kuppermann, USA

Overview of Pathways and Treatments for Dry AMD

T. Hohman, USA

Anti C5 in Dry AMD

J. Mones, Spain

A Phase 2 Study of Encapsulated CNTF Secreting Cell Implant (NT-501) in Patients with Geographic Atrophy Associated with Dry AMD

J.S. Heier, USA

Alprostadil for Dry Age Related Macular Degeneration (AMD)

A.J. Augustin, Germany

Fenretinide for Dry AMD

J.S. Heier, USA

GAP and GATE

T. Hohman, USA

Progress in the Development of ACU-4429 for the Treatment of Dry AMD

J. W. Chandler, USA

Macular Pigment Imaging in AREDS II Participants: An Ancillary Study of AREDS II Subjects Enrolled at the Moran Eye Center

P. Bernstein, USA

16:00 – 17:30 **Session: Trends Treating Ocular Problems**
Chair: S. Dikstein, Israel

Intracellular Effect of Polyols on Gene Expression

T. Biro, Hungary

Conjunctivochalasis

J. Nemeth, Hungary

Eye Drops With and Without Preservatives

TBA





The Contribution of the Meibomian Gland Dysfunction to Ocular Diseases

A. Bron, UK

Hyperosmotic Treatment of Corneal Edema

Z. Nagy, Hungary

18:00 - **Welcome Reception**

Friday – December 2nd, 2011

08:00 – 09:00 **Session: Wet AMD Panel - Cases Discussion**

Management of Wet AMD in the CATT and VEGF-Trap Era

Panel: J. Heier, USA, **P. Kaiser**, USA, **U. Schmidt-Erfurth**, Austria,
& **A. Loewenstein**, Israel

08:00 – 09:00 **Session: Cornea Cases**

Chair: P. Asbell, USA

Corneal Mass & Severe Keratitis

O. Ucakhan-Gunduz, Turkey

The Use for Toric Intraocular Lenses Topographically Confirmed Irregular
Astigmatism

J. Gayton, USA

TBA

P. Asbell, USA

09:00 – 10:30 **Session: Wet AMD I**

Chair: B. Kuppermann, USA

Role of Inflammation in AMD and DR

A.J. Augustin, Germany

Gene Therapy for Wet AMD

J.S. Heier, USA

Targeting Platelet Derived (PDGF) and Vascular Endothelial (VEGF) Growth
Factors for Neovascular AMD – Phase 1 Study

P. Kaiser, USA

Efficacy of a Topical Tubulin Inhibitor, OC-10X, in a Non-Human Primate Model
of Exudative AMD

C. Greven, USA

VIEW-1 and VIEW-2

U. Schmidt-Erfurth, Austria





Lucentis (Ranibizumab) versus Avastin (Bevacizumab) for CNV/AMD

A. Loewenstein, Israel

Macular EpiRetinal Brachytherapy in Treated Age Related Macular Degeneration Patients (MERITAGE and CABERNET)

J.S. Heier, USA

Externally-Applied Stereotactic Orthovoltage Irradiation for Age-Related Macular Degeneration: Results of a Phase I Clinical Trial

P. Kaiser, USA

09:00 – 09:45

Session: Toxicology

Chair: F.W. Fraunfelder, USA

Fluoroquinolone Induced Uveitis

E. Suhler, USA

The Role of Poly Pharmacy in Causing Dry Eye

F.T. Fraunfelder, USA

Optic Neuritis Associated with Anti-Tnf and Other Biologic Therapies Used in Auto-Immune Inflammatory Diseases

K. Winthrop, USA

09:00 – 09:45

Session: Intraocular Pressure and Glaucoma

Chair: J. Jonas, Germany & **H. Reitsamer**, Austria

IOP Contact Lenses

C. Faschinger, Austria

Aqueous Dynamics and IOP

H. Reitsamer, Austria

The Pressure Concept in Glaucoma Medical Therapy

A. Hommer, Austria

Vasopressin and IOP and Blood Flow

B. Bogner, Austria

New Glaucoma Shunt Implants

H. Reitsamer, Austria

09:45 – 10:30

Session: Antioxidants and Nutrition

Chair: P. Bernstein, USA

TBA

P. Bernstein, USA

Nutritional, Genetic, and Environmental Effects on the Eye

J. Seddon, USA

Recent Bioavailability Studies on Various AREDS Formulations

E. Johnson, USA





09:45 – 10:30	Session: Glaucoma Therapy and Ocular Surface Chair: J. Jonas , Germany & H. Reitsamer , Austria
	Ocular Surface in General TBA Conjunctival Impression Cytology for the Evaluation of Ocular Surface Changes E.M. Haller-Schober , Austria Ocular Surface Disease in Glaucoma Patients J. Horwath-Winter , Austria Effect of Inflammatory Cytokines Present in Tears from Chronically Medicated Glaucoma Patients as a Predictor of Glaucoma Surgery Failure T. Wong , Singapore
10:30 – 11:00	Coffee Break
11:00 – 11:45	Sponsored Session – Sponsored by Bayer
11:45 – 12:30	Session: Retinal Degeneration Chair: B. Kuppermann , USA
	Overview of Retinal Degenerations J. Sahel , France Neuroprotection in Retinal Degenerations, An Overview J. Sahel , France Cone Viability Factors: Molecular and Functional Studies J. Sahel , France Cis Beta Carotene for Congenital Stationary Night Blindness Y. Rotenstreich , Israel
11:45 – 12:30	Session: Imaging Chair: S. Binder , Austria
	TBA W. Drexler , Austria 3D-Visualisation of OCT, Present and Future Advantage C. Glittenberg , Austria The Choroid with New Technology M. Esmaelpour , Austria Intraoperative OCT Guided Macular Surgery S. Binder , Austria
11:45 – 12:30	Session: Ethics – Round Table Discussion
12:30 – 13:30	Sponsored Lunch Break – Sponsored by Bausch & Lomb





14:00 – 15:30

Session: Diabetic Macular Edema I

Chair: B. Kuppermann, USA

Triamcinolone Acetonide and Diabetic Macular Edema

P. Lanzetta, Italy

Laser Plus Steroids for DME

F. Bandello, Italy

Lucentis for DME-RETAIN/RESOLVE/SUSTAIN

F. Bandello, Italy

Laser Plus Anti-VEGF for Diabetic Macular Edema

A.J. Augustin, Germany

DRCRnet Studies

M. Ip, USA

Iluvien FAME for DME

B. Kuppermann, USA

How do Steroids Work on Macular Edema? Towards a Rationale Choice

F. Behar, France

The Potency of Glucocorticoids: What do We Measure?

F. Behar, France

Lucentis for DME Clinical Trials RIDE, RISE, and READ-2/RESOLVE/SUSTAIN

TBA

Cytokine Concentration in Aqueous Humour of Eyes with Diabetic Macular Edema

J. Jonas, Germany

14:00 – 14:45

Session: Gene Therapy

Chair: C. Paterson, USA

Gene Therapy for neovascular AMD

A. Scaria, USA

From Virus Evolution to Vector Revolution

D. Grimm, Germany

Gene Therapy of CNG Channelopathies of the Retina

M. Seeliger, Germany





14:00 – 15:30

Session: Clinical Studies for Uveitis + Free Papers

Moderator: R. Neumann, Israel

Endpoints and Standards of Reference

E. Anglade, USA

Biomarkers

TBA

Adaptive Protocols for Clinical Studies

M. De Smet, Switzerland

Posterior Scleritis in Children

G. Cheung, Singapore

14:45 – 15:30

Session: Nanotechnology

Chair: U.B. Kompella, USA & L. Schmetterer, Austria

Nanosystems for Drug and Gene Delivery to the Eye

U.B. Kompella, USA

Nanotechnology-Guided Molecular Imaging of Retinal Inflammation

A. Jayagopal, USA

Lipid Nanoparticulate Carriers for Anti-Inflammatory Drug Delivery to the Posterior Segment of Eye

E.B. Souto, Portugal

15:30 – 16:00

Coffee Break

16:00 – 16:45

Session: Diabetic Retinopathy

Chair: B. Kuppermann, USA

TA/Steroids for Inhibition of Progression of DR

M. Ip, USA

Role of the Vitreous in Diabetic Retinopathy Progression

A. Gandorfer, Germany

Microaneurysms as Predictors for Progression and Regression of Diabetic Retinopathy - Post-Hoc Results from the DIRECT Programme

A.K. Sjolie, Denmark

Pathogenic Role of Activating Transcription Factor 4 in Muller Cell-Derived Inflammation Cytokine Production in Diabetic Retinopathy

S. Zhang, USA

16:00 – 17:30

Session: Drug Delivery

Chair: D. Tang-Liu, USA & R. Gurny, Switzerland

Application of Releasable Linker Technology to Ophthalmic Drug Delivery

D. Santi, USA





Retinal Drug Delivery: Challenges and Advances

P. Hughes, USA

Development of Encapsulated Cell Therapy for Treating Retinal Diseases

W. Tao, USA

TBA

A. Heiligenhaus, Germany

Non Viral Gene Transfer for Protein Delivery to the Retina

F. Behar, France

Nanoscaled Delivery Systems for Topical Application

C. Di Tommaso, Switzerland

Sustained Release of L-Lactate to the Posterior Segment of the Eye for Vasodilation of the Retinal Arteries

M. Veurink, Switzerland

Prodrug Delivery of Cyclosporine A for the Treatment of Dry Eye

M. Rodriguez, Switzerland

Pharmacokinetics of Biopharmaceuticals in the Eye

J.M. Combette, Switzerland

Efficient Penetration of a Topical Anti-TNF- α Antibody Fragment into the Anterior Chamber of the Human Eye

D. Escher, Switzerland

Session: Anterior Segment Imaging / Devices

16:00 – 17:30

Chair: P. Asbell, USA

The Use of Imaging to Confirm of Diagnosis and Treatment Efficacy of Narrow Angle Glaucoma

J. Gayton, USA

Advances in Anterior Segment Optical Coherence Tomography Imaging

J.S. Mehta, Singapore

New Methods for Riboflavin Corneal Delivery for Corneal Collagen Cross-Linking

B.S. Fant, USA

Assessment of a New Device for Conjunctival Impression

P. Roy, France

Oculus Keratograph to Measure Tear Break Up Time

R. Toyos, USA

Scheimpflug Imaging in Keratoconus

O. Ucakhan-Gunduz, Turkey





16:45 – 17:30

Session: Devices & Drug Delivery

Chair: B. Kuppermann, USA

Biodegradable Microspheres for Retinal Diseases

R. Herrero-Vanrell, Spain

The Use of Nanospheres Loaded Thermo-Responsive Hydrogel for
Dexamethasone Sodium Phosphate Ocular Delivery

J. Kang-Mieler, USA

OCT in Diabetic Retinopathy

A. Pollack, Israel

The Role of Ischemia in AMD Progression as Manifested by the Retinal
Function Imager (RFI)

A. Loewenstein, Israel

Saturday – December 3rd, 2011

08:00 – 09:00

Session: Ocular Infectious Diseases – Case Presentation

Moderator: C. Deuter, Germany

08:00 – 09:00

Session: Glaucoma – Case Presentation

Moderator: J. Jonas, Germany & H. Reitsamer, Austria

09:00 – 10:30

Session Therapy of Retinal/Choroidal Angiogenesis + Free Papers

Chair: A. Das, USA

Remodeling of Retinal Vasculature by Glial Cells from the Optic Nerve

D. Sinha, USA

Epigenetic Regulation of Intraocular Angiogenesis

D. Hinton, USA

Role of Rap1 GTPase in Reducing CNV in an Animal Model

M. Hartnett, USA

Ocular Angiogenesis Research in the Ranibizumab Era

J. Penn, USA

TBA

R. Caldwell, USA

09:00 – 09:45

Session: Blood Flow and Glaucoma

Chair: J. Jonas, Germany & H. Reitsamer, Austria

Blood Flow and Glaucoma

G. Garhöfer, Austria





The Role of Blood Flow in the Management of Glaucoma: a 25 Year Perspective

A. Harris, USA

TBA

Pfeiffer, Germany

New Insights into Optic Nerve Head Blood Flow Regulation

L. Schmetterer, Austria

09:00 – 10:30

Session: Dry Eye Treatment Innovations + Free Papers

Chair: P. Asbell, USA

TBA

S. Barabino, Italy

Liposomes and Bioadhesive Polymers Combined for Dry Eye Treatment

R. Herrero-Vanrell, Spain

Eye Detec Follow up

B. Linder, USA

Treatment of Dry Eyes

C. Tan, Singapore

Effect of Aminoacid Enriched Artificial Tear in the Management of Dry Eye

P. Aragona, Italy

Acupuncture to Support the Treatment of Dry Eye Disease

T. Blechschmidt, Switzerland

Intense Pulse Light Treatment for Dry Eye Syndrome

R. Toyos, USA

Effects of Long Term Use of NSAIDs in Dry Eye Patients

R. Toyos, USA

09:45 – 10:30

Session: OID Treatment Updates

Moderators: R. Neumann, Israel & **T. Barisani**, Austria

CME in Uveitis - Still a Challenge

S. Androudi, Greece

The New Candidate Drugs for Uveitis Patients

TBA

TNF Inhibitors

Y. Elshabrawi, Austria

10:30 – 11:00

Coffee Break





11:00 – 12:30	Session: Inhibition of Diabetic Retinopathy + Free Papers Chair: A. Das, USA
	Mitochondria Biogenesis and Diabetic Retinopathy R. Kowluru, USA
	Retinal Vascular Basement Membrane - A Potential Therapeutic Target in Diabetic Retinopathy S. Roy, USA
	Endothelial Progenitor Cells in Therapy of Diabetic Retinopathy M. Grant, USA
	Diabetic Retinal Vascular Dysfunction Involves Arginase R.W. Caldwell, USA
11:00 – 11:45	Sponsored Session – Sponsored by Novagali
11:00 – 12:30	Session: Dry Eye / Ocular Surface Clinical Trials Chair: P. Asbell, USA
	Biomarkers S. Bonini, Italy
	TBA K. Brazzell, USA
	Cytokine Targeting In Dry Eye Disease- Results Of a Randomized Double Masked Clinical Trial R. Dana, USA
	Biomarker and Tear Film F. Grus, Germany
	New Drug Development – Challenges to the Small Firm G. Novack, USA
	Biomarkers for Inflammation of the Ocular Surface P. Asbell, USA
	Report on the Safety and Efficacy of a Multi-Center Phase II Clinical Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye G. Cumberlidge, USA
	Effects of Long Term Use of NSAIDs in Dry Eye Patients R. Toyos, USA
11:45 – 12:30	EVER Symposium
12:30 – 13:30	Lunch Break – Sponsored Lunch – Sponsored by Thrombogenics





14:00 – 14:45 **Session: Diabetic Retinopathy Free Papers**
Chair: B. Kuppermann, USA

14:00 – 15:30 **Session: Regulation of Ophthalmic Products Around the World & Discussion**
Chair: M. Eydelman, USA

Recent Modifications to the FDA's Regulatory Paradigm
M. Eydelman, USA

Evolution in FDA Perspective on Endpoints in Ophthalmology
W. Chambers, USA

TBA
J. Cunha-Vaz, Portugal

TBA
K. Wickstrom, Sweden

14:00 – 15:30 **Session: Allergic Conjunctivitis**
Chair: E.K. Akpek, USA

Immunobiology of Conjunctival Mast Cells in Health and Disease
V. Calder, UK

Role of Lymphocytes in Allergic Conjunctivitis
M. Stern, USA

Challenges of Clinical Trials in Chronic Allergic Conjunctivitis
S. Bonini, Italy

Vernal Keratoconjunctivitis as a Public Health Problem
M. Calonge, Spain

Atopic Keratoconjunctivitis: Epidemiology and Clinical Findings
E.K. Akpek, USA

Evidence Based Treatment of Allergic Conjunctivitis
A. Aldave, USA

14:45 – 15:30 **Session: Macular Edema II**
Chair: B. Kuppermann, USA

Ozurdex for DME: Results of a Randomized Controlled Trial of an Intravitreal Dexamthasone Drug Delivery System in Diabetic Macular Edema
B. Kuppermann, USA

Intravitreal Bioerudivel Sustained-Release Triamcinolone Microspheres System (RETAAC) for the Treatment of Diabetic Macular Edema
J. Cardillo, Brazil





Ozurdex for Uveitic Macular Edema

M. De Smet, Switzerland

The DA VINCI Study: A Phase 2 Trial of VEGF Trap-Eye for Diabetic Macular

B. Kuppermann, USA

Integrin Inhibition for DME

B. Kuppermann, USA

15:30 – 16:00 **Coffee Break**

16:00 – 17:30 **Session: Wet AMD II**

Chair: B. Kuppermann, USA

Is There a Role for Surgery for Subretinal Hemorrhage in the Anti-VEGF Era?

D. Saperstein, USA

Ozurdex as Adjunctive Therapy to Lucentis in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

B. Kuppermann, USA

PDGF plus Lucentis for CNV

P. Kaiser, USA

Lucentis for non-AMD CNV

M. Goldstein, Israel

Intravitreal Ranibizumab for Neovascular AMD in Real World Clinical Settings

P. Lanzetta, Italy

Fusion Regimen of Ranibizumab: Combination of OCT Guided Retreatment with Fixed Retreatment (PRN + FIXED) for Wet AMD

J. Mones, Spain

Rationale of Anti PDGF + Anti VEGF in Wet AMD

J. Mones, Spain

Triple Therapy for Wet AMD

A.J. Augustin, Germany

A Comparison of Combination Therapy Trials for Wet AMD

P. Kaiser, USA

16:00 – 16:45 **Session: Vascular Targets + Free Papers**

Chair: L. Schmetterer, Austria

Role of Ischemia/Oxidative Stress in the Pathogenesis of POAG

N. Osborne, USA

Autoregulation in Glaucoma

S. Orguel, Switzerland

Dynamic Autoregulation in the Eye

L. Wang, USA





16:00 – 17:30

Session: Ocular Infections

Panel: I. Barequet, Israel

Keratitis Treatment Update 2011: Comparison of Fortified Cefuroxime/Gentamicin to Cefazolin/Tobramycin and Moxifloxacin Monotherapy
R. Kowalski, USA

FDA Contact Lens Research and Recommendations
M. Eydelman, USA

TBA
L. Xie, China

The Chameleon of Herpetic Keratitis
B. Seitz, Germany

Perioperative Prophylaxis of Endophthalmitis After Cataract Surgery
T. Suzuki, USA

Evaluation of Ocular Antibiotics
E. Romanowski, USA

The Antibacterial Effectiveness of Ultraviolet A/Riboflavin Corneal Cross-Linking in Different Pathogenic Infectious Keratitis
I. Barequet, Israel

Sunday – December 4th, 2011

09:00 – 09:45

Session: Various Retinal Diseases

Panel: B. Kuppermann, USA

FA Still Necessary in AMD and DME?
J. Mones, Spain

Pros and Pitfalls of Anti-VEGF Treatment in the Neonate
K. Drenser, USA

Ocriplasmin for the Treatment of sVMA. Results from the Phase III MIVI-TRUST Clinical Trials
P. Kaiser, USA

Intraocular VEGF Concentration and Refractive Error
J. Jonas, Germany

Update Regarding Use and Benefit of NSAIDs in Ophthalmology
W.F. Mieler, USA

Treatment and Prevention of Endophthalmitis 2011
W.F. Mieler, USA





Wnt-Driven Modulation of Capillary Growth and Maintenance

K. Dreiser, USA

Novel Therapeutic Targets in CSCR

F. Behar, France

08:00 – 09:00 **Session: Basic Science – Free Papers**

09:00 – 10:30 **Session: Conventional and Potential Glaucoma Therapy II + Free Papers**

Pharmacological Therapy of Glaucoma

F. Grehn, Germany

Pharmacogenetics in Glaucoma

G. Mossböck, Austria

Manipulation of the TM Cytoskeleton to Enhance Aqueous Outflow

P. Kaufman, USA

09:45 – 10:30 **Session: Basic Retina**

Panel: B. Kuppermann, USA

Non Viral Photoreceptor Transfection Without Detaching the Retina

F. Behar, France

The Retina: A Novel Mineralo Sensitive Target

F. Behar, France

Intraocular Cell-Based Production of Glucagon-Like Peptide-1

J. Jonas, Germany

Transcellular Pathway in RPE Cells

F. Behar, France

Cytokine Concentration in Aqueous Humour of Eyes with Exudative Age-Related Macular Degeneration

J. Jonas, Germany

10:30 – 11:00 **Coffee Break**

11:00 – 11:45 **Session: Retina Free Papers**

11:00 – 11:45 **Session: Anterior Segment Free Papers**

11:45 – 12:30 **Session: Glaucoma Free Papers**

11:45 – 12:30 **Session: OID Free Papers**

